Posters

      Compilation of in vitro studies evaluating the impact of exposure to aerosols from heated tobacco products and an electronic vapor device on oral health and dental esthetics

      Zanetti, F.; Nussbaum, A. K.; Iskandar, A.; Zhao, X.; Ren, Y.; Majeed, S.; Ivanov, N. V.; Peitsch, M. C.; Hoeng, J.

      Conference date
      Sep 14, 2020
      Conference name
      Deutsche Gesellschaft für Parodontologie
      Link to more information
      Topic
      Summary

      Cigarette smoke (CS) causes serious diseases and has detrimental effects on human health, including oral health. Smoking can lead to gingivitis, periodontitis, tooth loss, and mouth cancer. CS is also a risk factor for tooth discoloration. Pigmented compounds present in the particulate phase generated by combustion of tobacco may cause discoloration of dental hard tissues and restorative materials. Switching from cigarette smoking to using reduced-risk products (RRP) has the potential to reduce the harm and dental esthetic concerns associated with smoking. However, rigorous scientific studies are necessary to demonstrate the potentially reduced detrimental effects of exposure to aerosols from RRPs relative to those of exposure to CS. In this poster, we summarize the results of numerous in vitro studies that investigated the impact of exposure to aerosols from different RRPs (2 heated tobacco products [HTP] and 1 electronic vapor [e-vapor] product) on oral cell cultures and dental coloration. In addition, we present the results of a study aimed at characterizing the chemical compounds associated with tooth discoloration.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.